secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2026-08-05T20:02:14+00:00
Accession:  0001193125-26-335010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q2 2026 revenue $26.9M (+34% YoY); net loss improves 37% to $7.3M
--------------------------------------------------------------------------

- Diagnostic testing revenue $25.4M (+42% YoY) on 20,900 test volumes (+38%).
- Gross margin 82% (up 200 bps); operating expenses +7% vs revenue +34% shows leverage.
- Net loss $7.3M (improved 37%); Adjusted EBITDA loss $3.2M (improved 56%).
- FY 2026 revenue guidance maintained at $108-114M (midpoint ~25% growth); gross margin ~80%.
- Cash $30.0M, up 17% from Q1 2026; includes $6.5M from ATM program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/0001193125-26-335010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/bdsx-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer